

Exhibit 1

Exhibit 1 - Pending Claims in U.S. Serial No. 09/464,902

1-86. (Canceled)

87. An isolated nucleic acid molecule encoding a polypeptide comprising consecutive amino acids the sequence of which is identical to the sequence of a CDR region present in an anti-CCR5 antibody or a portion thereof, which antibody is selected from the group consisting of monoclonal antibody PA 14 (ATCC Accession No. HB-12610), monoclonal antibody PA 8 (ATCC Accession No. HB-12605), monoclonal antibody PA 9 (ATCC Accession No. HB-12606), monoclonal antibody PA 10 (ATCC Accession No. HB-12607), monoclonal antibody PA 11 (ATCC Accession No. HB-12608), and monoclonal antibody PA 12 (ATCC Accession No. HB-12609).

88. The nucleic acid molecule of claim 87, wherein the nucleic acid molecule is an RNA molecule, DNA molecule or cDNA molecule.

89-90. (Canceled)

91. The nucleic acid molecule according to claim 87, wherein the polypeptide binds to an epitope of CCR5, which epitope comprises amino acid residues in (1) an N-terminus of CCR5, (2) one of three extracellular loop regions of CCR5, or (3) a combination thereof.

92. The nucleic acid molecule according to claim 87, wherein the polypeptide is an Fab portion of an antibody.

93. The nucleic acid molecule according to claim 87, wherein the polypeptide is a variable domain of an antibody.

94. The nucleic acid molecule according to claim 87, wherein the polypeptide is an F(ab')₂ portion of an antibody.
95. The nucleic acid molecule according to claim 87, wherein the nucleic acid is present in a hybridoma selected from the group of hybridomas consisting of PA 14 (ATCC Accession No. HB-12610), PA 8 (ATCC Accession No. HB-12605), PA 9 (ATCC Accession No. HB-12606), PA 10 (ATCC Accession No. HB-12607), PA 11 (ATCC Accession No. HB-12608), and PA 12 (ATCC Accession No. HB-12609).
- 96-97. (Canceled)
98. The nucleic acid molecule according to claim 95, wherein the portion of the antibody is an Fab portion.
99. The nucleic acid molecule according to claim 95, wherein the portion of the antibody is a variable domain.
100. (Currently Amended) The nucleic acid molecule according to claim 95, wherein the portion of the antibody is an F(ab')₂ portion.
101. (Canceled)
102. The nucleic acid molecule of claim 87, wherein the antibody is monoclonal antibody PA14.
103. The nucleic acid molecule according to claim 87, wherein the polypeptide is a heavy chain of an antibody.
104. The nucleic acid molecule according to claim 87, wherein the polypeptide is a light chain of an antibody.

105. The nucleic acid molecule according to claim 87, wherein the polypeptide is a single chain antibody comprising heavy and light chains.
106. The nucleic acid molecule according to claim 95, wherein the hybridoma is PA14 (ATCC Accession No. HB-12610).
107. The nucleic acid molecule according to claim 95, wherein the portion of the antibody is a heavy chain.
108. The nucleic acid molecule according to claim 95, wherein the portion of the antibody is a light chain.
109. The nucleic acid molecule according to claim 95, wherein the polypeptide is a single chain antibody comprising heavy and light chains.